Fig. 3. Immune responses to prime/boost/boost intramuscular FEN-CRM197 immunization are enhanced in magnitude with dmLT and LTA1 adjuvants.
Groups of Balb/c mice (n = 3–5) were left naïve or immunized IM with 5 μg FEN-CRM ± 150 μg alum, 0.1 μg dmLT, or 5 μg LTA1 on weeks 0, 3, and 6. Two-weeks later (week 8) serum and bone-marrow was collected for antibody evaluations. a Schematic of immunization schedule. b Compiled Week 5 and Week 9 serum anti-CRM or anti-FEN (coating antigen indicated) serum IgG. c Compiled EU/ml of indicated serum anti-FEN serum IgG1, or IgG2a ELISAs. d Representative anti-FEN (TT-BSA coated) IgG/IgA ELISPOT images from bone-marrow of week 8 immunized mice. Blue spots indicate IgG and red spots IgA ASCs. e Compiled anti-FEN IgG ASC per 106 cells from bone-marrow. Bars at mean + s.e.m. with significance determined by ANOVA paired with Bonferroni post-hoc test as shown (*P < 0.05, **P < 0.01, ***P < 0.001).